Two cheap pitches, one documented structure: the market’s best-known flat rate against an aggressive price claim with thin paperwork behind it.
The two models
Henry Meds advertises the market’s best-known flat-rate compounded pricing — a structure we favor on principle, because flat rates make teaser math impossible. Whether the advertised flat number survives contact with membership terms, shipping, and dose realities is precisely what its pending verification pass will establish; until then, no Henry figure is published here.
Remedy Meds markets aggressively on price while publishing comparatively little about its clinical workflow, pharmacy sourcing, and full fee stack — the documentation gap itself is the finding so far. It sits in our verification queue, and until that pass completes, no Remedy figure or score appears on this site.
Verified vs pending — read this before the marketing
Neither provider on this page has completed price verification, so this comparison stays structural — business models, pricing architecture, and the questions each must answer — with zero advertised numbers repeated as facts. The only verified figures on this site today sit in the ledger.
Same promise, different auditability
Both sell “affordable”; only one publishes a structure you can stress-test before verification even runs. Henry’s flat-rate architecture makes specific, falsifiable claims — which is what our checkout pass will test. Remedy’s pitch leaves the fee stack, sourcing, and terms largely undocumented, which moves the whole burden onto the interrogation kit. Cheapness you can audit and cheapness you must take on faith are different products at the same advertised price.
Go deeper
Full files: Henry Meds · Remedy Meds. Decision tools: the quiz routes by coverage and priorities; the calculator turns any quote into a true 12-month number; the ledger holds every verified figure and every pending slot.